Zobrazeno 1 - 10
of 186
pro vyhledávání: ''
Autor:
Neal D. Shore, Joyce Steinberg, Bertrand Tombal, Ugo De Giorgi, Xun Lin, Qi Shen, Fred Saad, David F. Penson, Katarzyna Madziarska, Jennifer Sugg, Cora N. Sternberg, Eleni Efstathiou, Maha Hussain, Karim Fizazi
Publikováno v:
European journal of cancer, Vol. 159, p. 237-246 (2021)
BACKGROUND: Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with r
Autor:
Philippe Ruszniewski, Tahir Shah, Ulrich Frank Pape, Aude Houchard, Marianne Pavel, C. Lombard-Bohas, Xuan-Mai Truong Thanh, Francesco Panzuto, Ivan Borbath, Jarosław B. Ćwikła, Jaume Capdevila
Publikováno v:
Scientia
European journal of cancer (Oxford, England : 1990), Vol. 157, no.157, p. 403-414 (2021)
European journal of cancer (Oxford, England : 1990), Vol. 157, no.157, p. 403-414 (2021)
Lanreotide; Progression-free survival; Somatostatin Lanreótido; Supervivencia libre de progresión; Somatostatina Lanreòtid; Supervivència lliure de progressió; Somatostatina Introduction This prospective, single-arm, phase 2 study assessed the e
Autor:
Guilherme Cantuaria, Paul DiSilvestro, Kirsty Rhodes, Lucy Gilbert, Johanna Mäenpää, Christian Marth, Maria Jesus Rubio Pérez, Koji Matsumoto, Claire Garnier-Tixidre, Ayumi Shikama, Isabelle Ray-Coquard, Philipp Harter, Daniel M. Anderson, Magdalena Sikorska, Francesco Raspagliesi, Ignace Vergote, Mario Ouwens, Robert Hettle, Domenica Lorusso, Kathleen N. Moore, Andres Poveda, Nicoletta Colombo, Ronnie Shapira-Frommer
Publikováno v:
European Journal of Cancer. 157:415-423
BACKGROUND: In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone
Autor:
Sabrina A. Hogan, Reinhard Dummer, Alexander M. Menzies, Florentia Dimitriou, Georgina V. Long
Publikováno v:
European Journal of Cancer. 157:214-224
Background Immune checkpoint inhibitors (ICIs) have activity across many tumor types, but activation of the immune system may also lead to significant, often steroid-refractory immune-related adverse events (irAEs). We sought to determine the activit
Autor:
Marie C Semira, Francis Parnis, Angelyn Anton, Peter Gibbs, Arun Azad, Javier Torres, Lavinia Spain, Ashray Gunjur, Andrew Weickhardt, Phillip Parente, Jeffrey C. Goh, Edmond M. Kwan, Shirley Wong, Ben Tran, Carmel Pezaro, J. Shapiro
Publikováno v:
European Journal of Cancer. 157:485-492
INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related events (SREs), including symptomatic skeletal events (SSEs). Bone-modifying agents (BMAs) delay SREs and SSEs. However, the
Autor:
Minghua Ge, Yan-Yan Liu, Zhengdong Li, Liangfang Shen, Qingyuan Zhang, Yi Luo, Jifeng Feng, Ye Guo, W. Chen, Kun-Yu Yang, Xiaohui He, Kai Xue, Yan Sun, T. Lin, Xiao-Dong Zhu, Xiao Ming Huang, XinYing Chang, Chunmei Bai, Yan Zeng, Lin Wang
Publikováno v:
European Journal of Cancer. 156:35-45
Background The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/
Autor:
Mateusz Opyrchal, Kian-Huat Lim, Jace Webster, Saiama N. Waqar, Albert C. Lockhart, Ningying Wu, Christopher G. Maher, Nick Boice, Joel Picus, Andrea Wang-Gillam, Benjamin R. Tan, Feng Gao, Maria Q. Baggstrom, Abhi Acharya, Daniel Morgensztern, Ramaswamy Govindan
Publikováno v:
European Journal of Cancer. 154:102-110
Aim Aurora kinase A (AURKA) is a pleiotropic serine/threonine kinase that orchestrates mitotic progression. Paclitaxel stabilises microtubules and disrupts mitotic spindle assembly. The combination of AURKA inhibitor (alisertib) plus paclitaxel may b
Autor:
Ugo De Giorgi, Giovanni Bozza, Roberto Sabbatini, Maurizio Nicodemo, Massimo Aglietta, Sabrina Rossetti, Franco Morelli, Giovanni L. Pappagallo, Giovanni Re, Camillo Porta, Giorgia Razzini, Lucia Fratino, Gaetano Facchini, Michele Aieta, Alessandro D'Angelo, Francesco Carrozza, Marco Maruzzo, Orazio Caffo, Paola Ermacora, Isabella Vittimberga, Erica Palesandro, Stefania Kinspergher, Sebastiano Buti, Monica Giordano, Daniela Scapoli, Franco Nolè, Luca Galli, Claudia Mucciarini, Donatello Gasparro, Cinzia Ortega, Chiara Ciccarese, Elena Verri, Francesca Maines, Giuseppe Schepisi, Francesca Valcamonico, Roberto Iacovelli, Antonello Veccia, Vittorina Zagonel, Caterina Messina, Donata Sartori, Paolo Lippe
Publikováno v:
European Journal of Cancer. 155:56-63
Background Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen receptor translocation and signalling. The aim of this study is to assess the efficacy of their concurrent administration in the first-line treatment for met
Autor:
Jonathan A. Ledermann, Rebecca Asher, Michael Friedlander, Ilan Bruchim, Sarah J. Lord, Eric Pujade-Lauraine, Ronnie Shapira-Frommer, Clare L. Scott, Ursula A. Matulonis, Amit M. Oza, Philipp Harter, Charlie Gourley, Tomasz Huzarski, Val Gebski, Angelina Tjokrowidjaja, Chee Khoon Lee, Ignace Vergote, Manuel Rodrigues, Werner Meier, Tsveta Milenkova
Publikováno v:
European Journal of Cancer. 154:190-200
Background The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not r
Autor:
Shunichi Sugawara, Junji Kishimoto, Hajime Asahina, Kenji Sugio, Yukari Tsubata, Yoshihiro Miyata, Kana Watanabe, Kosuke Hamai, Taishi Harada, Takahiro Uchida, Isamu Okamoto, Satoshi Oizumi, Kentaro Tanaka, Kunihiko Kobayashi
Publikováno v:
European Journal of Cancer. 149:14-22
Background Osimertinib is now a standard treatment for patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated whether the combination of osimertinib with cytotoxic chemotherapy might hold a